Half Year 2024 Circio Holding ASA Earnings Call TranscriptAug 29, 2024kr1.35 (+3.86%)Earnings- Q4 2022 Targovax ASA Earnings Call TranscriptFeb 16, 2023kr31.09 (+3.35%)Earnings
- Q3 2022 Targovax ASA Earnings Call TranscriptNov 03, 2022kr34.41 (-2.35%)Earnings
- Q2 2022 Targovax ASA Earnings Call TranscriptAug 18, 2022kr42.58 (-8.06%)Earnings
- Q1 2022 Targovax ASA Earnings Call TranscriptMay 12, 2022kr44.12 (-4.97%)Earnings
- Q4 2021 Targovax ASA Earnings Presentation TranscriptFeb 17, 2022
- Q3 2021 Targovax ASA Earnings Call TranscriptNov 04, 2021kr125.93 (-6.31%)Earnings
- Q2 2021 Targovax ASA Earnings Call TranscriptAug 18, 2021kr167.1 (-5.48%)Earnings
- Q1 2021 Targovax ASA Earnings Call TranscriptMay 06, 2021kr179.21 (-4.39%)Earnings
- Targovax ASA Corporate Analyst Meeting TranscriptFeb 18, 2021
- Targovax ASA - Special Call TranscriptDec 02, 2020
- Q3 2020 Targovax ASA Earnings Call TranscriptNov 05, 2020kr166.13 (+9.94%)Earnings
- Q2 2020 Targovax ASA Earnings Call TranscriptAug 20, 2020kr159.35 (-2.52%)Earnings
- Targovax ASA Corporate Analyst Meeting TranscriptJun 25, 2020
- Q1 2020 Targovax ASA Earnings Call TranscriptMay 07, 2020kr197.61 (-7.80%)Earnings
- Q4 2019 Targovax ASA Earnings Call TranscriptMar 11, 2020kr106.56 (-10.02%)Earnings
- Targovax ASA - Pre Recorded Special Call TranscriptJan 21, 2020
- Targovax ASA - Special Call TranscriptNov 15, 2019
- Q3 2019 Targovax ASA Earnings Call TranscriptNov 07, 2019kr125.69 (+2.77%)Earnings
- Q2 2019 Targovax ASA Earnings Call TranscriptAug 22, 2019kr134.89 (-4.30%)Earnings
- Q1 2019 Targovax ASA Earnings Call TranscriptMay 09, 2019kr153.78 (-3.79%)Earnings
Targovax ASA - Pre Recorded Special Call Transcript
¤ -
Welcome. My name is Magnus Jäderberg. I'm the Chief Medical Officer of Targovax. I have the pleasure today to present to you our hot off the press data in mesothelioma, and specifically, malignant pleural mesothelioma. So this is a highly malignant solid tumor disease in the lining of the lungs. And one of the real diagnostic challenges with this disease is that the symptoms of the disease comes very late in the disease process, which means that when you've finally diagnosed a patient, very often, in fact, in most cases, it's too late for surgery, that all we can do as physicians is to provide chemotherapy.
Now there is one combination, pemetrexed/cisplatin, that is the standard of care for these patients, and it's been around for about 15 years, so nothing new has actually happened in those -- that time period. And that's the main reason why we have decided to study this disease when we add ONCOS-102, our oncolytic virus to standard-of-care chemotherapy.
Now the trial that we have conducted, and where we're now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
